

Supplemental table 2: McNemar Tests

Laboratory data that assisted with heparin anticoagulation monitoring				
	24-hour period		72-hour period	
	OR (95 th percentile)	p-value	OR (95 th percentile)	p-value
ACT	1.6 (0.46 – 6.22)	0.58	2.25 (0.63 – 10.00)	0.27
PTT	1.33 (0.41 – 4.66)	0.79	5.00 (1.07 – 46.93)	0.04
Anti-factor Xa	1.40 (0.38 – 5.59)	0.77	1.33 (0.41 – 4.66)	0.79
Laboratory data that assisted with blood product administration				
	24-hour period		72-hour period	
	OR (95 th percentile)	p-value	OR (95 th percentile)	p-value
Platelet count	1.25 (0.44 – 3.65)	0.81	2.67 (0.64 – 15.61)	0.23
PT	1.33 (0.23 – 9.10)	> 0.99	0.50 (0.05 – 3.49)	0.68
Fibrinogen	2.67 (0.64 – 15.60)	0.23	2.33 (0.53 – 13.98)	0.34
D-Dimer	-	0.48	-	> 0.99

*Activated clotting time, ACT; partial thromboplastin time, PTT; prothrombin time, PT; OR, odds ratio.

Aim: To evaluate if abnormal coagulation laboratory tests during 24-hour and 72-hour periods prior to the event are associated with cerebrovascular complications.

Hypothesis: Abnormal coagulation laboratory tests during 24-hour and 72-hour periods prior to the event are associated with cerebrovascular complications. Coagulation laboratory tests during ECMO were classified into 2 categories: 1) data that assisted with heparin anticoagulation monitoring including ACT (seconds), PTT (seconds), and anti-factor Xa (International Units per milliliter), and 2) data that assisted with blood product administration including platelet count (per microliter), PT (seconds), fibrinogen (milligrams per deciliter) and D-dimer (micrograms per milliliter).

Results: Paired matched case-control study design was utilized. Cases were defined as patients with acute cerebrovascular events (intracranial hemorrhage and infarct). Cases were matched 1:1 with appropriate controls. McNemar tests were performed individually for each of the coagulation laboratory tests between the cases and controls, comparing both 24-hour median values as well as 72-hour median values. None of the tests indicated significant association between the presence of abnormal coagulation profile and cerebrovascular events, except for 72-hour period PTT.